BioNotebook: Emergent/Cangene, Sprout, Agios/Celgene, Sutro, Savient/Crealta
This article was originally published in Scrip
Executive Summary
Emergent buys Cangene for $222m; Sprout appeals FDA rejection; Agios, Celgene extend collaboration; Sutro raises $26m Series D; and Savient liquidates to Crealta.
You may also be interested in...
Agios, Celgene Target Accelerated Approvals For Precision AML Medicines
Celgene Corp. will pursue accelerated approval later this year for AG-221 (enasidenib), the lead drug candidate under its partnership with Agios Pharmaceuticals Inc., which may separately seek accelerated approval for its wholly-owned drug AG-120 in 2017, giving Agios's precision medicines a foothold in the oncology market while the collaborators work to expand the labeling for their drugs.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.